Your browser doesn't support javascript.
loading
Inhibition of N-type calcium channels by phenoxyaniline and sulfonamide analogues.
Bispat, Anjie S; Cardoso, Fernanda C; Hasan, Md Mahadhi; Dongol, Yashad; Wilcox, Ricki; Lewis, Richard J; Duggan, Peter J; Tuck, Kellie L.
Afiliação
  • Bispat AS; School of Chemistry, Monash University Victoria 3800 Australia Kellie.Tuck@monash.edu.
  • Cardoso FC; CSIRO Manufacturing, Research Way Clayton Victoria 3168 Australia Peter.Duggan@csiro.au.
  • Hasan MM; Institute for Molecular Bioscience, The University of Queensland St Lucia QLD 4072 Australia.
  • Dongol Y; Institute for Molecular Bioscience, The University of Queensland St Lucia QLD 4072 Australia.
  • Wilcox R; Institute for Molecular Bioscience, The University of Queensland St Lucia QLD 4072 Australia.
  • Lewis RJ; School of Chemistry, Monash University Victoria 3800 Australia Kellie.Tuck@monash.edu.
  • Duggan PJ; Institute for Molecular Bioscience, The University of Queensland St Lucia QLD 4072 Australia.
  • Tuck KL; CSIRO Manufacturing, Research Way Clayton Victoria 3168 Australia Peter.Duggan@csiro.au.
RSC Med Chem ; 15(3): 916-936, 2024 Mar 20.
Article em En | MEDLINE | ID: mdl-38516585
ABSTRACT
Building on previous investigations, structural modifications to the neuronal calcium ion channel blocker MONIRO-1 and related compounds were conducted that included replacement of the amide linker with an aniline and isosteric sulfonamide moiety, and the previously used strategy of substitution of the guanidinium group with less hydrophilic amine functionalities. A comprehensive SAR study revealed a number of phenoxyaniline and sulfonamide compounds that were more potent or had similar potency for the CaV2.2 and CaV3.2 channel compared to MONIRO-1 when evaluated in a FLIPR-based intracellular calcium response assay. Cytotoxicity investigations indicated that the sulfonamide analogues were well tolerated by Cos-7 cells at dosages required to inhibit both calcium ion channels. The sulfonamide derivatives were the most promising CaV2.2 inhibitors developed by us to date due, possessing high stability in plasma, low toxicity (estimated therapeutic index > 10), favourable CNS MPO scores (4.0-4.4) and high potency and selectivity, thereby, making this class of compounds suitable candidates for future in vivo studies.

Texto completo: 1 Base de dados: MEDLINE Idioma: En Revista: RSC Med Chem Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Revista: RSC Med Chem Ano de publicação: 2024 Tipo de documento: Article